News | May 11, 2023
FSD Pharma completes dosing of first cohort in Phase I clinical trial of Lucid-MS
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
The Awards recognizes standout digital health & medical technology products and companies
ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer
Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation
Launches Thalassemia Bal Sewa Yojana portal and releases standard treatment guidelines for sickle cell anemia disease
APP13007 is a novel aqueous nanosuspension formulation for the treatment of inflammation and pain following ocular surgery
PredOmix has developed a novel blood test that can detect about 32 cancers in both men and women with 98 percent accuracy
The planned bioprocessing facility would support commercial manufacturing for biotech and pharmaceutical customers across Asia-Pacific.
The partnership will commercialize four nasal sprays with a combined Global IQVIA market size in excess of $400m
Subscribe To Our Newsletter & Stay Updated
